Immunomedics Inc. is preparing to launch Trodelvy (sacituzumab govitecan), the first antibody-drug conjugate for triple-negative breast cancer (TNBC) and its first commercial product, despite the challenges of launching a new drug in the current COVID-19 pandemic. The company laid out the strategy it will use to drive rapid brand awareness and adoption of Trodelvy and establish Immunomedics as a respected oncology partner during an investor call.
Immunomedics' Trodelvy Will Be First ADC For Triple-Negative Breast Cancer
Trodelvy was granted an accelerated approval by the US FDA based on a Phase II study. It is the first commercial product for Immunomedics.
More from Anticancer
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
More from Therapy Areas
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.